American biotech firm focused on neurodegenerative diseases
Recent studies have shown significant advances in gene therapy for hearing loss and eye conditions, as well as promising research on reversing brain inflammation linked to aging. Meanwhile, new evidence questions the effectiveness of Alzheimer’s drugs, highlighting ongoing challenges in neurodegenerative treatments. Today's date is Mon, 27 Apr 2026 11:37:39 +0100.
Biogen’s tau-targeting drug diranersen has shown potential in reducing tau levels and slowing cognitive decline in a small subset of a 400-person study, prompting plans for a larger trial. The results, presented at the Alzheimer’s Association International Conference in London, are cautiously optimistic but require confirmation in bigger studies.